AU3309697A - Compositions and methods for treating specific gene expression-related diseases and disorders in humans - Google Patents

Compositions and methods for treating specific gene expression-related diseases and disorders in humans

Info

Publication number
AU3309697A
AU3309697A AU33096/97A AU3309697A AU3309697A AU 3309697 A AU3309697 A AU 3309697A AU 33096/97 A AU33096/97 A AU 33096/97A AU 3309697 A AU3309697 A AU 3309697A AU 3309697 A AU3309697 A AU 3309697A
Authority
AU
Australia
Prior art keywords
disorders
humans
compositions
methods
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33096/97A
Inventor
Sudhir Agrawal
Robert W. Coombs
R. Russell Martin
Paul J. Schechter
Christophe Tournerie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Publication of AU3309697A publication Critical patent/AU3309697A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU33096/97A 1996-06-18 1997-06-11 Compositions and methods for treating specific gene expression-related diseases and disorders in humans Abandoned AU3309697A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2041796P 1996-06-18 1996-06-18
US60020417 1996-06-18
PCT/US1997/010143 WO1997048795A2 (en) 1996-06-18 1997-06-11 Compositions and methods for treating specific gene expression-related diseases and disorders in humans

Publications (1)

Publication Number Publication Date
AU3309697A true AU3309697A (en) 1998-01-07

Family

ID=21798518

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33096/97A Abandoned AU3309697A (en) 1996-06-18 1997-06-11 Compositions and methods for treating specific gene expression-related diseases and disorders in humans

Country Status (2)

Country Link
AU (1) AU3309697A (en)
WO (1) WO1997048795A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19855469C2 (en) * 1998-12-01 2001-01-11 Michael Esrich Method for determining the apolipoprotein E genotype in a human sample
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2104717T3 (en) * 1990-08-16 1997-10-16 Isis Pharmaceuticals Inc OLIGONUCLEOTIDES TO MODULATE THE EFFECTS OF CYTOMEGALOVIRUS INFECTIONS.
US5442049A (en) * 1992-11-19 1995-08-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating the effects of cytomegalovirus infections
US5801235A (en) * 1994-05-25 1998-09-01 Hybridon, Inc. Oligonucleotides with anti-cytomegalovirus activity

Also Published As

Publication number Publication date
WO1997048795A2 (en) 1997-12-24
WO1997048795A3 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
AU6974996A (en) Compositions for the treatment of dermatological disorders and methods for their use
AU5439996A (en) Compositions and methods for treating pain
GR3036364T3 (en) Compositions and methods for treating or preventing inflammatory diseases
AU4655296A (en) Compositions and methods for treating tumor cells
AU1296099A (en) Methods and compositions for treating dermatoses
AU6952896A (en) Method for treatment of cancer and infectious diseases and compositions useful in same
EP1005345A4 (en) Methods and compositions for treating allergic asthma and other disorders using descarboethoxyloratadine
AU2327599A (en) Compositions and methods for treating autoimmune diseases
AU3725997A (en) S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
AU7622198A (en) Methods of treating mental diseases, inflammation and pain
AU6714396A (en) Methods and compositions for treating cell proliferative disorders
AU2542097A (en) Oligonucleotide treatments and compositions for human melanoma
AU2804297A (en) Method of and composition for treating disorders of the skin using vitamin k
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
AU1734895A (en) Methods and compositions for treatment of periodontal disease and repair of periodontal lesions
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
AU3768795A (en) Method and compositions for hair treatment
AU5298699A (en) Dnazymes and methods for treating hpv-related disorders
AU6242498A (en) Methods for treating central and peripheral nerve pain
AU5333298A (en) Compositions and methods for tumour therapy
AU3204899A (en) Hair treatment composition and method
AU4823999A (en) Methods and compositions for treating diseases mediated by transglutaminase activity
AU6252699A (en) Composition and method for treating allergic diseases
AU6592496A (en) Compositions and methods for treating specific gene expression-related diseases and disorders in humans
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders